he program will explore how to overcome barriers to immune cell entry into tumors, as well as insufficient activation of anti-tumor immune responses. In addition, diverse immune cell therapies will be covered, from T-cell based mainstays like TILs, gene-modified T cells, and CAR-T cells, to emerging modalities deploying innate immune cells like dendritic and NK cells.
the topics covered will engage discussions around: antibody-based protein degraders; next-generation antibody drug conjugate technologies; precision biologics; increasing accessibility of antibody drugs on a global scale; advances in combination biology and modalities
Participants will hear from pioneers in each of these areas, representing diverse perspectives and backgrounds. Potential workshops include: “New Horizons in Artificial Intelligence,” “Therapeutics for Healthy Aging,” and “The Regenerative Potential of Stem Cells in Aging”. This program is a unique opportunity to bring together leaders in the aging field from academia and industry who share the common goals of promoting healthy aging and combating age-associated disease.
Participants will be able to: Discuss the latest clinical trials and recommendations for active surveillance in prostate cancer management, including lifestyle interventions and dietary recommendations; evaluate the effectiveness and limitations of surgical interventions for urinary incontinence
The theme this year is “Hope, Heal, Learn”- 3 principles that make up the essence of work. The course faculty will provide multiple talks in various plenary sessions, as well as presentations in subspecialty breakout sessions and moderated panel conversations
There will be an opportunity on Day 2 to practice clinical reasoning and professional boundary skills with a standardized patient regarding personal/professional/prescribing/sexual / and financial relationships and boundaries
In addition to experiencing mock oral exams that are realistic, participants will also receive immediate feedback and guidance from expert oral examiners, as well as the opportunity to refine their thought process, communication skills, approach to oral exam question types, and decision-making ability
The cutting-edge AACR IO 2025 program will appeal to a wide audience of basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. A mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits will cover the spectrum of the IO field – including late-breaking clinical trials sessions highlighting new agents and IO combinations, and the results of practice-changing.
This is a synergistic pairing, given that lipodystrophy has long been known to promote severe MAFLD and ways to reduce overall obesity are also being tried for MAFLD, such as with bariatric surgery and now GLP-1 and dual GLP-1/GIP agonists. Joint sessions on human genetics and therapeutics across MASH and obesity will facilitate interaction between endocrinologists, hepatologists, adipose and liver biologists for synergy
Sessions will highlight roles of non-myocytes (including immune cells and adipocytes), advances in precision medicine, and a variety of topics that impact diverse populations (including sex disparities, aging, and co-morbidities that often disproportionally impact underserved populations).
An update on the pathophysiology of the major mood and anxiety disorders will be described including new data on inflammation. The latest data on suicide will be presented including risk factors and strategies for prevention. Treatment of depression, anxiety, and women’s psychiatric disorders will be described.
The lectureship will focus on topics related to cerebrovascular disease, such as carotid stenosis, carotid endarterectomy, and stroke aiming to deepen participants' understanding of these areas, improving their clinical competence and patient care performance.
